Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Obesity Drug Maker Takes Slow Road

Posted by: Arlene Weintraub on July 20, 2009

On July 20, Orexigen Therapeutics was living the dream of small companies everywhere. It announced that its experimental drug Contrave was safe and that it helped obese people lose weight—a combination of attributes that few pharmaceutical companies have been able to achieve. Orexigen’s stock skyrocketed 32% to $7.50 before the market opened.

But Orexigen doesn’t plan to file for FDA approval until 2010. That means the drug wouldn’t be on the market until late next year at the very earliest. For a company that had virtually no revenues and $93 million in losses last year, that’s an awfully long time to wait for what could be a hit product.

But in this case, CEO Mike Narachi is probably smart to take a lot of time putting together a really convincing case for the FDA. Contrave is a combination of buproprion, an anti-depressant, and naltrexone, a drug to treat addiction. The FDA has been particularly hard on drugs that act in the brain, because of the risk that they may cause dangerous side effects, such as suicidal tendencies. In fact, pharmaceutical giant Sanofi-Aventis stopped developing its obesity product, Acomplia, last year because of such concerns.

Contrave curbs appetite by attacking two pathways in the brain: one that controls cravings and one that increases metabolism. In three trials involving 3,800 patients, about half of patients lost at least 5% of their body weight. By contrast, fewer than 20% of patients taking a placebo lost that much weight.

There were a handful of serious side effects reported, though, including two seizures. And FDA investigators are likely to ask for details about how patients’ moods held up during the one-year trials. It will be interesting to see how this tiny company shoulders such big expectations for a promising drug.

Reader Comments


July 20, 2009 4:33 PM

The questions would be 1) how long is the treatment and would the effects last? and 2) the 'real' risk vs. benefit that shot down previous attempts. It is really hard to use drugs to take care of a basic human instinct, ie. eating, on overdrive....


July 21, 2009 10:40 AM

Don't you think "losing weight" is very subjective here? For as much as I know, our weight consists of muscles, water, body fats and bones. If this drug do help to lose weight, which of these 4 components will it aim to reduce? I'm sure many people want to lose their fats and not the rest.


December 5, 2009 1:27 AM

Everybody seems to look for an answer in a pill. There's all sorts of anti-anxiety drugs out there, and one of the most common side-effects listed for these drugs is suicide.

So many women (and men) are duped into believing that they can take a pill and lose weight. Most of these pills have very high caffeine levels, and that is simply horrible for the body and the nerves.

The weight gain did not happen all at once, and losing it won't happen all at once either. It all comes in small, positive baby steps. Eat slightly less. Get slightly more active. And believe it or not, it starts to come off.

We can't depend on drugs for every issue we have. Sometimes we just need to improve our habits.

diets that work

Post a comment



How can you manage smarter? Bloomberg Businessweek contributors synthesize insights from the brightest business thinkers, critique the latest management trends, and comment on leaders in the news.

BW Mall - Sponsored Links

Buy a link now!